Zobrazeno 1 - 10
of 13
pro vyhledávání: '"V V Pavan Kedar Mukthinuthalapati"'
Autor:
V V Pavan Kedar Mukthinuthalapati, Samuel Akinyeye, Zachary P Fricker, Moinuddin Syed, Eric S Orman, Lauren Nephew, Eduardo Vilar-Gomez, James Slaven, Naga Chalasani, Maya Balakrishnan, Michelle T Long, Bashar M Attar, Marwan Ghabril
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0211811 (2019)
BackgroundSafety-net hospitals provide care for racially/ethnically diverse and disadvantaged urban populations. Their hospitalized patients with cirrhosis are relatively understudied and may be vulnerable to poor outcomes and racial/ethnic dispariti
Externí odkaz:
https://doaj.org/article/842206048a4d44098365fd6791e0e864
Autor:
V. V. Pavan Kedar Mukthinuthalapati, Vikash Sewram, Ntokozo Ndlovu, Stephen Kimani, Ashraf Omar Abdelaziz, Elizabeth Yu Chiao, Ghassan K. Abou-Alfa
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 756-766 (2021)
More than 80% of global hepatocellular carcinoma (HCC) patients are estimated to occur in sub-Saharan Africa (SSA) and Eastern Asia. The most common risk factor of HCC in SSA is chronic hepatitis B virus (HBV) infection, with the incidence highest in
Externí odkaz:
https://doaj.org/article/a84ffa7e73a44adc9ed14698534ac32e
Publikováno v:
Annals of Translational Medicine. 11:32-32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75e67934a3f5628688f20dacbfc46965
https://doi.org/10.21037/atm-22-5875
https://doi.org/10.21037/atm-22-5875
Autor:
V V Pavan Kedar Mukthinuthalapati, Sean Smith, Sunny R K Singh, Muhammad Zain Farooq, Aakash Putta, Shweta Gupta
Publikováno v:
Clinical lung cancer. 21(5)
Lung cancer screening (LCS) with annual low-dose computed tomography in high-risk groups decreases the mortality related to lung cancer. Its implementation rate has been low, and knowledge relating to LCS has not been assessed in providers treating u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0011094bc1b11ef5cda88790b10fe17d
https://pubmed.ncbi.nlm.nih.gov/32389506
https://pubmed.ncbi.nlm.nih.gov/32389506
Autor:
Muhammad Ebad Ur Rehman, Nisar Asmi, Sheeba Habeeb Ba Aqeel, V V Pavan Kedar Mukthinuthalapati, Muhammad Saad Farooq, Muhammad Zain Farooq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcf6e5efac6d4d482eaf25a0c2efda65
https://doi.org/10.26226/morressier.5ce26eb0fa2a705fd90c60b9
https://doi.org/10.26226/morressier.5ce26eb0fa2a705fd90c60b9
Autor:
V. V. Pavan Kedar Mukthinuthalapati, Seema Gandhi, Carol Czapar, Bashar M. Attar, Yazan Abu Omar, Vikas Nath
Publikováno v:
Cureus.
A 49-year-old lady with no past medical history presented with dysphagia and 40-pound weight loss, which occurred over eight months. On physical examination, she had proximal muscle weakness and crackles in basilar regions of the lungs. Labs were sig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c3af2b783059e7c50eaa861700ef7a2
https://doi.org/10.7759/cureus.4139
https://doi.org/10.7759/cureus.4139
Publikováno v:
Journal of gastrointestinal oncology. 9(5)
Background: Sorafenib is first line chemotherapy for advanced hepatocellular carcinoma (HCC). There are little real-world experiences with sorafenib done on US population except for the US arm of the GIDEON study, a phase IV multi-national study. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f89c23beefa0c1f8d5922b2cd8bc252c
https://pubmed.ncbi.nlm.nih.gov/30505582
https://pubmed.ncbi.nlm.nih.gov/30505582
Autor:
V. V. Pavan Kedar Mukthinuthalapati, Tejinder Randhawa, Yuchen Wang, Sanjay A Patel, Estefania Flores, Tiago Araujo, Yazan Abu Omar, Ishaan Vohra, Pedro Palacios
Publikováno v:
American Journal of Gastroenterology. 114:S546-S547
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45534509314c9aa607493db322bd25a4
https://doi.org/10.14309/01.ajg.0000593292.51922.de
https://doi.org/10.14309/01.ajg.0000593292.51922.de
Autor:
V V Pavan Kedar Mukthinuthalapati, Muhammad Zain Farooq, Ankit Mangla, Muhammad Saad Farooq, Sheeba Ba Aqeel, Prasanth Lingamaneni, Paul G. Rubinstein, Aakash Putta
Publikováno v:
Blood. 134:4963-4963
Introduction: Current expert recommendations recommend double therapy (DT) over triple therapy (TT) in atrial fibrillation patients post percutaneous coronary intervention (PCI) to prevent the incidence of stroke. Though previous studies have focused
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6808a5b6ba7579b88dc39bb1d7dc84d4
https://doi.org/10.1182/blood-2019-129607
https://doi.org/10.1182/blood-2019-129607
Autor:
Irbaz Bin Riaz, Hani M. Babiker, Muhammad Zain Farooq, Saad Ullah Malik, V V Pavan Kedar Mukthinuthalapati, Tariq Jamal Siddiqi, Nisar Asmi, M. Hassan Murad, Sri Harsha Patlolla, Noman Lateef
Publikováno v:
Journal of Clinical Oncology. 37:e13096-e13096
e13096 Background: Several studies have reported the association between atrial fibrillation (AF) and malignant cancer. Recently, results from a large cohort within the Women’s Health Study showed increased incident risk of breast, colon and lung c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e3110d839c9d80c80a9384406628474
https://doi.org/10.1200/jco.2019.37.15_suppl.e13096
https://doi.org/10.1200/jco.2019.37.15_suppl.e13096